Danaher Co. (NYSE:DHR) Shares Bought by Hemenway Trust Co LLC

Hemenway Trust Co LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 0.1% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 154,941 shares of the conglomerate’s stock after acquiring an additional 205 shares during the quarter. Danaher comprises about 3.3% of Hemenway Trust Co LLC’s portfolio, making the stock its 10th largest position. Hemenway Trust Co LLC’s holdings in Danaher were worth $38,712,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DHR. Patrick M Sweeney & Associates Inc. boosted its holdings in shares of Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares during the period. Trust Co of Kansas boosted its holdings in shares of Danaher by 4.1% in the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after acquiring an additional 40 shares in the last quarter. Abacus Planning Group Inc. lifted its position in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the period. ST Germain D J Co. Inc. lifted its position in Danaher by 1.4% in the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the period. Finally, Godsey & Gibb Inc. lifted its position in Danaher by 3.0% in the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after purchasing an additional 42 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is owned by insiders.

Danaher Trading Up 1.3 %

DHR stock traded up $3.35 during midday trading on Friday, hitting $268.06. The stock had a trading volume of 438,386 shares, compared to its average volume of 2,774,216. The firm has a market cap of $198.55 billion, a PE ratio of 45.52, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company’s 50-day moving average price is $260.98 and its 200 day moving average price is $255.61.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter last year, the business earned $2.05 EPS. On average, equities research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent analyst reports. Robert W. Baird raised their price objective on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Evercore ISI dropped their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. The Goldman Sachs Group increased their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Danaher in a report on Friday. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.